ERBB2 and breast carcinoma: A further study of BRAF/MEK pathway activity from TCGA and 43 microarray datasets found downregulation of BRAF/MEK pathways in breast cancer compared with normal breast tissue, except for HER2-positive and triple-negative tumors.